On January 29, 2026, President Donald Trump revealed that Eli Lilly has committed to constructing six new pharmaceutical manufacturing plants across the United States over the next five years. In a call with Lilly’s CEO, Trump emphasized the company’s strategy to expand its domestic footprint, citing sites in Indiana, North Carolina, Ohio, Texas, Colorado and Michigan. The new facilities are expected to create approximately 3,200 direct jobs and an additional 4,500 positions among contractors and suppliers. This investment represents Lilly’s largest single domestic expansion since its 2019 insulin capacity increase, reinforcing the company’s supply-chain resilience and potential to accelerate production of both small-molecule and biologics therapies.

Eli Lilly is positioning itself at the forefront of an industry transformation, with analysts forecasting that more than 50% of novel medicines approved by 2030 will incorporate artificial-intelligence assistance. Leveraging its repository of over 2.5 million patient-level clinical trial records, Lilly has partnered with NVIDIA to build a dedicated AI supercomputer and co-innovation lab in Cambridge, Massachusetts. The initiative, launched in December 2025, aims to reduce early-stage drug discovery timelines by up to 40%, targeting next-generation candidates in diabetes, obesity and Alzheimer’s disease. Management estimates that AI-driven workflows could add $4.7 billion in incremental revenue by 2030 through faster candidate selection and optimized trial design.

On January 28, 2026, Eli Lilly and Repertoire Immune Medicines entered into a strategic collaboration valued at up to $1.93 billion to co-develop therapies for multiple autoimmune diseases, including rheumatoid arthritis and multiple sclerosis. Under the agreement, Lilly will contribute $250 million in upfront and R&D funding, while Repertoire is eligible for up to $1.68 billion in development, regulatory and commercial milestones plus tiered royalties. The alliance grants Lilly exclusive global rights to several Repertoire-discovered bispecific antibody candidates currently in preclinical evaluation, with the first IND filing expected by mid-2027.

Eli Lilly has also forged a global research and licensing agreement with Germany-based Seamless Therapeutics to develop programmable recombinase-based treatments for genetic hearing loss. Under terms disclosed on January 28, Lilly will pay over $1.12 billion, including an undisclosed upfront payment and committed R&D funding, plus additional milestone payments and royalties. Seamless’ proprietary platform enables large, site-specific DNA insertions independent of cellular repair pathways, potentially addressing mutations in several high-prevalence hearing-loss genes. Lilly aims to advance the lead program into IND-enabling studies by early 2027, leveraging its clinical development expertise in rare genetic disorders.